Adjusted outcome analyses according to treatment strategy
. | . | RD for OS at 5 y, % . | RD for PFS at 5 y, % . | RD for TFS at 5 y, % . | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Training cohort . | Variable . | RD . | 95% CI . | P . | RD . | 95% CI . | P . | RD . | 95% CI . | P . |
All | MR | 8 | 1 to 15 | .019 | 15 | 7 to 24 | <.001 | 10 | 3 to 17 | .007 |
FLIPI | ||||||||||
Low | — | — | — | — | — | — | — | — | — | |
Intermediate | −1 | −11 to 8 | NS | 4 | −9 to 18 | NS | 2 | −9 to 13 | NS | |
High | −11 | −20 to −2 | .016 | −14 | −26 to −2 | .023 | −8 | −18 to 2 | NS | |
Bulk | −4 | −10 to 3 | NS | −10 | −18 to −1 | .025 | −5 | −12 to 2 | NS | |
FL grade 3A | −4 | −12 to 4 | NS | −3 | −14 to 7 | NS | −4 | −13 to 4 | NS | |
+Anthracycline | 4 | −3 to 11 | NS | 9 | −1 to 18 | NS | 7 | −1 to 15 | NS | |
Female sex | 0 | −6 to 7 | NS | 4 | −4 to 13 | NS | 4 | −3 to 11 | NS | |
R-CHOP/CHOP-like | MR | 10 | 1 to 20 | .049 | 23 | 10 to 35 | <.001 | 12 | 1 to 23 | .028 |
FLIPI | ||||||||||
Low | — | — | — | — | — | — | — | — | — | |
Intermediate | 2 | −13 to 17 | NS | 8 | −11 to 27 | NS | 4 | −13 to 20 | NS | |
High | −7 | −20 to 7 | NS | −18 | −36 to −1 | .048 | −5 | −20 to 10 | NS | |
Bulk | 0 | −11 to 10 | NS | −7 | −21 to 7 | NS | −5 | −17 to 6 | NS | |
FL grade 3A | −2 | −12 to 8 | NS | 0 | −13 to 14 | NS | −5 | −16 to 7 | NS | |
Female sex | −3 | −13 to 8 | NS | 4 | −9 to 17 | NS | 3 | −8 to 14 | NS | |
R-CVP/CVP-like | MR | 7 | −3 to 17 | NS | 11 | −2 to 24 | NS | 10 | −1 to 21 | NS |
FLIPI | ||||||||||
Low | — | — | — | — | — | — | — | — | — | |
Intermediate | −2 | −15 to 12 | NS | 5 | −16 to 25 | NS | 1 | −14 to 17 | NS | |
High | −16 | −30 to −2 | .025 | −18 | −37 to 1 | NS | −14 | −29 to 1 | NS | |
Bulk | −6 | −16 to 3 | NS | −11 | −23 to 2 | NS | −5 | −16 to 5 | NS | |
FL grade 3A | −4 | −18 to 11 | NS | −8 | −27 to 11 | NS | −4 | −20 to 11 | NS | |
Female sex | 4 | −6 to 13 | NS | 7 | −6 to 20 | NS | 9 | −2 to 20 | NS |
. | . | RD for OS at 5 y, % . | RD for PFS at 5 y, % . | RD for TFS at 5 y, % . | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Training cohort . | Variable . | RD . | 95% CI . | P . | RD . | 95% CI . | P . | RD . | 95% CI . | P . |
All | MR | 8 | 1 to 15 | .019 | 15 | 7 to 24 | <.001 | 10 | 3 to 17 | .007 |
FLIPI | ||||||||||
Low | — | — | — | — | — | — | — | — | — | |
Intermediate | −1 | −11 to 8 | NS | 4 | −9 to 18 | NS | 2 | −9 to 13 | NS | |
High | −11 | −20 to −2 | .016 | −14 | −26 to −2 | .023 | −8 | −18 to 2 | NS | |
Bulk | −4 | −10 to 3 | NS | −10 | −18 to −1 | .025 | −5 | −12 to 2 | NS | |
FL grade 3A | −4 | −12 to 4 | NS | −3 | −14 to 7 | NS | −4 | −13 to 4 | NS | |
+Anthracycline | 4 | −3 to 11 | NS | 9 | −1 to 18 | NS | 7 | −1 to 15 | NS | |
Female sex | 0 | −6 to 7 | NS | 4 | −4 to 13 | NS | 4 | −3 to 11 | NS | |
R-CHOP/CHOP-like | MR | 10 | 1 to 20 | .049 | 23 | 10 to 35 | <.001 | 12 | 1 to 23 | .028 |
FLIPI | ||||||||||
Low | — | — | — | — | — | — | — | — | — | |
Intermediate | 2 | −13 to 17 | NS | 8 | −11 to 27 | NS | 4 | −13 to 20 | NS | |
High | −7 | −20 to 7 | NS | −18 | −36 to −1 | .048 | −5 | −20 to 10 | NS | |
Bulk | 0 | −11 to 10 | NS | −7 | −21 to 7 | NS | −5 | −17 to 6 | NS | |
FL grade 3A | −2 | −12 to 8 | NS | 0 | −13 to 14 | NS | −5 | −16 to 7 | NS | |
Female sex | −3 | −13 to 8 | NS | 4 | −9 to 17 | NS | 3 | −8 to 14 | NS | |
R-CVP/CVP-like | MR | 7 | −3 to 17 | NS | 11 | −2 to 24 | NS | 10 | −1 to 21 | NS |
FLIPI | ||||||||||
Low | — | — | — | — | — | — | — | — | — | |
Intermediate | −2 | −15 to 12 | NS | 5 | −16 to 25 | NS | 1 | −14 to 17 | NS | |
High | −16 | −30 to −2 | .025 | −18 | −37 to 1 | NS | −14 | −29 to 1 | NS | |
Bulk | −6 | −16 to 3 | NS | −11 | −23 to 2 | NS | −5 | −16 to 5 | NS | |
FL grade 3A | −4 | −18 to 11 | NS | −8 | −27 to 11 | NS | −4 | −20 to 11 | NS | |
Female sex | 4 | −6 to 13 | NS | 7 | −6 to 20 | NS | 9 | −2 to 20 | NS |
Pseudo values approach, nonproportional hazards. Bold values represent significant P values (P < .05).